Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / NOS1

NOS1

Basics

Aliases:
This biomarker is also known as:
  • NOS type I,
  • constitutive NOS,
  • nNOS,
  • Peptidyl-cysteine S-nitrosylase NOS1,
  • NOS,
  • neuronal NOS,
  • IHPS1,
  • NC-NOS,
  • peptidyl-cysteine S-nitrosylase NOS1,
  • EC 1.14.13.39,
  • bNOS,
  • Constitutive NOS,
  • N-NOS,
  • nitric oxide synthase 1 (neuronal),
  • Neuronal NOS,
  • nitric oxide synthase, brain,

View in BioMuta

Description…

NOS1, or nitric oxide synthase 1 (neuronal), along with inducible nitric oxide synthase (NOS2) and endothelial nitric oxide synthase (NOS3), catalyze the generation of nitric oxide and L-citrulline from L-arginine and molecular oxygen. Nitric oxide is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, nitric oxide displays many properties of a neurotransmitter. NOS1 also displays antimicrobial and antitumoral activities.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: NOS1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data available.

Performance Comment

NOS1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.